Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Wu, Y; Amonkar, MM; Sherrill, BH; O'Shaughnessy, J; Ellis, C; Baselga, J; Blackwell, KL; Burstein, HJ

Published Date

  • June 1, 2019

Published In

Volume / Issue

  • 30 / 6

Start / End Page

  • 1019 -

PubMed ID

  • 30624581

Pubmed Central ID

  • 30624581

Electronic International Standard Serial Number (EISSN)

  • 1569-8041

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdy531

Language

  • eng

Conference Location

  • England